Delivery Order SPE2DB22D2211-SPE2DB25FSEHM
- Not listed
- The Defense Logistics Agency awarded a $5,864.45 delivery order to AmerisourceBergen Drug Corp for Emgality 120 mg/mL pen injectors on September 4, 2025, with completion targeted for September 5, 2025. This non-competitive delivery order represents a firm fixed price transaction under AmerisourceBergen's larger contract vehicle with DLA. The pharmaceutical product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. Emgality is a CGRP monoclonal antibody...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 29, 2025, for the supply of Emgality 120 mg/ml pen injectors, with a ceiling value of $1,527.12. This is a firm fixed price delivery order with an ultimate completion date of September 30, 2025, and represents a non-set-aside competitive award. The order will be fulfilled from AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Emgality 120 mg/ml pen injectors, with a ceiling value of $1,554.86. This firm fixed-price delivery order is scheduled for completion by July 22, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award was made without a set-aside designation, indicating open competition. This delivery order is issued under...
- The Defense Logistics Agency awarded a $2,348.61 delivery order to AmerisourceBergen Drug Corp for Emgality 120 mg/ml pen injectors on September 4, 2025, with a completion date of September 5, 2025. This competitively awarded, firm fixed-price contract has no set-aside designation and is performed at the contractor's facility in Conshohocken, Pennsylvania. Emgality is a calcitonin gene-related peptide monoclonal antibody used in migraine prevention, reflecting the Defense Logistics Agency's...
- The Defense Logistics Agency awarded a delivery order valued at $1,309.49 to AmerisourceBergen Drug Corp for Emgality 120 mg/mL pen injectors on May 20, 2025, with an ultimate completion date of May 21, 2025. This is a firm fixed-price delivery order with no set-aside designation, issued under competitive procedures. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. Emgality is a migraine prevention medication, reflecting the company's role as a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 6, 2025, for the supply of Emgality 120 mg/ml pen injectors, valued at $3,458.00. This firm fixed-price contract, which is non-set-aside and competitively awarded, is scheduled for completion by August 7, 2025, with performance occurring at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Emgality 120 mg/mL pen injectors, valued at $1,556.10. This is a firm fixed-price delivery order with an ultimate completion date of August 29, 2025, and represents a non-competitive set-aside award. The pharmaceutical will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters and primary distribution operations. This...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,037.40 to AmerisourceBergen Drug Corp for Emgality 120 mg/ml pen injectors. This non-set-aside, competitively awarded contract was issued on September 16, 2025, with an ultimate completion date of September 17, 2025, and reflects a firm fixed-price delivery order structure. The product will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. Emgality is a CGRP monoclonal antibody...
- The Defense Logistics Agency (DLA) awarded a $3,457 delivery order to AmerisourceBergen Drug Corp for Emgality 120 mg/ml pen injectors on September 18, 2025, with an ultimate completion date of September 19, 2025. This competitive, firm fixed-price contract was issued without set-aside designation and represents a child order under AmerisourceBergen's larger contract vehicle with DLA. The product—Emgality (erenumab)—is a monoclonal antibody used for migraine prevention, reflecting the...
- The Defense Logistics Agency awarded a delivery order valued at $1,729.00 to AmerisourceBergen Drug Corp for the supply of Emgality 120 mg/ml pen injectors. This competitively awarded, firm fixed-price delivery order was issued on June 2, 2025, with an ultimate completion date of June 3, 2025. The contract represents a child order under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and...
- SPE2DB22D2211Indefinite Delivery Contract
- SPE2DB22D2211-SPE2DB25FSEHMDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 5, 2025, for the supply of Emgality 120 mg/mL pen injectors, with a ceiling value of $1,037.40. This firm fixed-price delivery order, which is not set-aside, is scheduled for completion by September 8, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Emgality is a CGRP monoclonal antibody indicated for migraine prevention, representing a specialty pharmaceutical product within the Defense Logistics Agency's medical supply chain. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. This prime contract vehicle serves as a comprehensive global pharmaceutical support mechanism enabling AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to military healthcare programs worldwide, including support for the Defense Health Agency and U.S. Coast Guard. The competitively awarded delivery order reflects AmerisourceBergen's established position as a critical pharmaceutical distributor for federal military and veteran healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.0k | 9/5/25 |